Close Menu

Tissue-Based Testing

News on immunohistochemistry and other tissue-based testing methods.

Promega will develop its microsatellite instability assay as a companion diagnostic for Incyte's anti-PD-1 drug candidate retifanlimab in endometrial cancer.

The companies hope to combine their technologies to provide pharmaceutical customers with an end-to-end workflow for multiplex histological staining and imaging. 

Of the eight patients who received drugs recommended by the tumor board based on data from the drug sensitivity assay, 75 percent responded.

The aim of the study is to establish a tumor registry based on blood and bone marrow samples from cancer patients with linked outcomes data, which the firm can use for precision drug development.

Researchers have identified immune cell gene expression signatures that could one day be developed into tests to predict response to treatment.